Literature DB >> 7495076

Differences in the interactions of lupus anticoagulant IgG with human prothrombin and bovine prothrombin.

L V Rao1, A D Hoang, S I Rapaport.   

Abstract

Lupus anticoagulant (LA) IgGs have been reported to inhibit more effectively and consistently the Xa/Va/phospholipid complex-catalyzed activation of human prothrombin that the Xa/Va/phospholipid complex-catalyzed activation of bovine prothrombin. This led us to carry out studies to determine whether the ability to inhibit the activation of prothrombin of LA IgGs, separated from the plasma of 15 patients by protein A affinity chromatography, could be related to the ability of the LA IgGs to bind to prothrombin under various experimental conditions. Of 14 LA IgG preparations tested all prolonged to a variable but substantial extent the dilute Russell's viper venom time (dRVVT) of human plasma but only minimally prolonged the dRVVT of bovine plasma. In a purified prothrombin activation system with a rate limiting concentration of phospholipid, all 15 LA IgG preparations inhibited the activation of human prothrombin with the majority showing > 50% of inhibition. In contrast, only one LA IgG markedly inhibited (> 50%) the activation of bovine prothrombin and five others moderately inhibited (25-40%) the activation of bovine prothrombin. Nevertheless, the majority of LA IgG preparations bound to immobilized bovine prothrombin on a Western blot and also to immobilized bovine prothrombin on a microtiter well. In an ELISA in which phosphatidylserine (PS) was immobilized on microtiter wells, bovine prothrombin supported the binding of 10 of 15 LA IgG preparations to PS. However, the extent of binding was lower than that observed with human prothrombin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495076

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Authors:  Savino Sciascia; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

2.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

3.  Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

Authors:  Mathivanan Chinnaraj; William Planer; Vittorio Pengo; Nicola Pozzi
Journal:  Blood Adv       Date:  2019-06-11

4.  Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome.

Authors:  Vittorio Pengo; Lorena Zardo; Maria Grazia Cattini; Elisa Bison; Elena Pontara; Sara Altinier; Chunyan Cheng; Gentian Denas
Journal:  TH Open       Date:  2020-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.